Do analysts prefer ELAN or MOR?

Elanco Animal Health currently has a consensus price target of $29.70, suggesting a potential upside of 32.49%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer RDY or MOR?

Dr. Reddy's Laboratories currently has a consensus price target of $732.40, indicating a potential upside of 5,628.59%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer MOR or AXSM?

Axsome Therapeutics has a consensus price target of $275.74, suggesting a potential upside of 76.39%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Axsome Therapeutics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable earnings and valuation, MOR or AXSM?

Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Axsome Therapeutics $638.50M 12.82 -$183.17M -$3.75 N/A

Do analysts recommend LNTH or MOR?

Lantheus currently has a consensus price target of $107.44, indicating a potential upside of 7.42%. Given Lantheus' stronger consensus rating and higher possible upside, equities analysts plainly believe Lantheus is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 11 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.21 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, LNTH or MOR?

Lantheus has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.16 MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is LNTH or MOR more profitable?

Lantheus has a net margin of 17.69% compared to MorphoSys' net margin of -226.79%. Lantheus' return on equity of 28.10% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% MorphoSys -226.79% -694.31% -22.55%

MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 10/12/2026

Compare

MOR vs. ELAN, RDY, AXSM, LNTH, and AMRX

Should you buy MorphoSys stock or one of its competitors? MorphoSys's main competitors and comparable companies include Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Lantheus (LNTH), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MorphoSys compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Elanco Animal Health had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Elanco Animal Health and 0 mentions for MorphoSys. Elanco Animal Health's average media sentiment score of 0.42 beat MorphoSys' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Elanco Animal Health	Neutral
MorphoSys	Neutral

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Elanco Animal Health has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $29.70, suggesting a potential upside of 32.49%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MorphoSys has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.38	-$232M	-$0.41	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Elanco Animal Health has a net margin of -3.96% compared to MorphoSys' net margin of -226.79%. Elanco Animal Health's return on equity of 8.13% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Elanco Animal Health beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Dr. Reddy's Laboratories' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
MorphoSys	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.98	$456M	$0.44	29.06
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Dr. Reddy's Laboratories currently has a consensus price target of $732.40, indicating a potential upside of 5,628.59%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats MorphoSys on 11 of the 14 factors compared between the two stocks.

How does MorphoSys compare to Axsome Therapeutics?

MorphoSys (NASDAQ:MOR) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Axsome Therapeutics has a net margin of -24.68% compared to MorphoSys' net margin of -226.79%. Axsome Therapeutics' return on equity of -265.55% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Axsome Therapeutics and 0 mentions for MorphoSys. Axsome Therapeutics' average media sentiment score of 0.08 beat MorphoSys' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Axsome Therapeutics	Neutral

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Axsome Therapeutics	$638.50M	12.82	-$183.17M	-$3.75	N/A

Axsome Therapeutics has a consensus price target of $275.74, suggesting a potential upside of 76.39%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Axsome Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Lantheus?

Lantheus (NASDAQ:LNTH) and MorphoSys (NASDAQ:MOR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Lantheus currently has a consensus price target of $107.44, indicating a potential upside of 7.42%. Given Lantheus' stronger consensus rating and higher possible upside, equities analysts plainly believe Lantheus is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lantheus has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.16
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

99.1% of Lantheus shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to MorphoSys' net margin of -226.79%. Lantheus' return on equity of 28.10% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Lantheus had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Lantheus and 0 mentions for MorphoSys. Lantheus' average media sentiment score of 0.63 beat MorphoSys' score of 0.00 indicating that Lantheus is being referred to more favorably in the media.

Company	Overall Sentiment
Lantheus	Positive
MorphoSys	Neutral

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Lantheus beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and MorphoSys (NASDAQ:MOR) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Amneal Pharmaceuticals has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.07	$72.06M	$0.49	39.94
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Amneal Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 7.31%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Amneal Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Amneal Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 0 mentions for MorphoSys. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat MorphoSys' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
MorphoSys	Neutral

Amneal Pharmaceuticals has a net margin of 5.05% compared to MorphoSys' net margin of -226.79%. Amneal Pharmaceuticals' return on equity of -584.46% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
MorphoSys	-226.79%	-694.31%	-22.55%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats MorphoSys on 15 of the 16 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.86B	$12.37B	$7.26B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-5.45	652.86	204.95	19.81
Price / Sales	11.99	749.54	562.00	81.34
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	54.17	9.21	10.75	6.03
Net Income	-$205.35M	$2.83B	$3.50B	$380.34M
7 Day Performance	N/A	-3.42%	-2.90%	-2.34%
1 Month Performance	N/A	-7.48%	-7.37%	-5.31%
1 Year Performance	N/A	-5.62%	2.97%	-2.94%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ELAN Elanco Animal Health	3.8086 of 5 stars	$22.30 -0.8%	$29.70 +33.2%	+11.9%	$11.23B	$4.72B	N/A	9,400
RDY Dr. Reddy's Laboratories	3.8983 of 5 stars	$12.25 -1.9%	$1,450.00 +11,738.7%	-10.9%	$10.43B	$3.58B	27.84	27,527	Analyst Upgrade
AXSM Axsome Therapeutics	3.148 of 5 stars	$172.97 -0.8%	$275.84 +59.5%	+29.0%	$9.13B	$638.50M	N/A	925	Analyst Forecast
LNTH Lantheus	3.499 of 5 stars	$100.18 +0.2%	$108.11 +7.9%	+83.2%	$6.52B	$1.54B	24.20	1,193	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. ELAN, RDY, AXSM, LNTH, and AMRX

How does MorphoSys compare to Elanco Animal Health?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Summary

How does MorphoSys compare to Axsome Therapeutics?

Summary

How does MorphoSys compare to Lantheus?

Summary

How does MorphoSys compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. ELAN, RDY, AXSM, LNTH, and AMRX

How does MorphoSys compare to Elanco Animal Health?

Does the media favor ELAN or MOR?

Do insiders & institutionals have more ownership in ELAN or MOR?

Which has more volatility and risk, ELAN or MOR?

Do analysts prefer ELAN or MOR?

Which has better earnings & valuation, ELAN or MOR?

Is ELAN or MOR more profitable?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Do insiders and institutionals have more ownership in RDY or MOR?

Is RDY or MOR more profitable?

Does the media prefer RDY or MOR?

Which has stronger valuation & earnings, RDY or MOR?

Do analysts prefer RDY or MOR?

Which has more volatility & risk, RDY or MOR?

Summary

How does MorphoSys compare to Axsome Therapeutics?

Is MOR or AXSM more profitable?

Which has more risk and volatility, MOR or AXSM?

Does the media refer more to MOR or AXSM?

Do insiders & institutionals have more ownership in MOR or AXSM?

Which has preferable earnings and valuation, MOR or AXSM?

Do analysts prefer MOR or AXSM?

Summary

How does MorphoSys compare to Lantheus?

Do analysts recommend LNTH or MOR?

Which has higher valuation & earnings, LNTH or MOR?

Do insiders and institutionals believe in LNTH or MOR?

Is LNTH or MOR more profitable?

Does the media prefer LNTH or MOR?

Which has more risk and volatility, LNTH or MOR?

Summary

How does MorphoSys compare to Amneal Pharmaceuticals?

Which has preferable earnings and valuation, AMRX or MOR?

Do analysts recommend AMRX or MOR?

Which has more volatility and risk, AMRX or MOR?

Does the media prefer AMRX or MOR?

Is AMRX or MOR more profitable?

Do institutionals & insiders believe in AMRX or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools